Loading
ERCC5 (DNA excision repair protein ERCC-5) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Skin cancer, Neuroendocrine tumours and 3 more.
Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3'incision in DNA nucleotide excision repair (NER). Binds and bends DNA repair bubble substrate and breaks base stacking at the single-strand/double-strand DNA junction of the DNA bubble.
CIViC holds 4 clinical evidence items and 0 assertions across 2 variants, naming Immune Checkpoint Inhibitor. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.97, animal model 0.57, genetic association 0.65, somatic mutation 0.98).
In plain words · ERCC5 (DNA excision repair protein ERCC-5) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Skin cancer, Neuroendocrine tumours and 3 more.
ERCC5 (DNA excision repair protein ERCC-5) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Skin cancer, Neuroendocrine tumours and 3 more.
Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3'incision in DNA nucleotide excision repair (NER).
No product in this corpus aims at ERCC5 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Germline variant: UniProt lists Xeroderma pigmentosum complementation group G (XP-G) under involvement in disease, and the record is a DNA repair gene; the medicines linked to it act through the loss (synthetic lethality) or use the variant to pick patients. HPA ERCC5: RNA low tissue specificity; high antibody staining in 9 normal tissues; highest cancer staining ovarian cancer (4 of 12 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Skin cancer (all types), Neuroendocrine tumours, Colorectal cancer, Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (xeroderma pigmentosum group G). (Rule 2 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P28715; Human Protein Atlas ERCC5 tissue; Open Targets ENSG00000134899 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Scherly et al, Nature, 1993, "Complementation of the DNA repair defect in Xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2". Source.
Sources: HGNC HGNC:3437 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P28715 (protein name, function text, keywords and locations (REST API)); CIViC gene ERCC5 (4 evidence items, 0 assertions, 2 variants; diseases: Melanoma, Lung Non-small Cell Carcinoma, Parietal Lobe Ependymoma, Cancer (GraphQL API, CC0)); Open Targets ENSG00000134899 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: colorectal cancer 0.51, ovarian cancer 0.57, melanoma 0.54, neuroendocrine neoplasm 0.52, skin cancer 0.56 (GraphQL API, CC0))
Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3'incision in DNA nucleotide excision repair (NER). Binds and bends DNA repair bubble substrate and breaks base stacking at the single-strand/double-strand DNA junction of the DNA bubble. Plays a role in base excision repair (BER) by promoting the binding of DNA glycosylase NTHL1 to its substrate and increasing NTHL1 catalytic activity that removes oxidised pyrimidines from DNA. Involved in transcription-coupled nucleotide excision repair (TCR) which allows RNA polymerase II-blocking lesions to be rapidly removed from the transcribed strand of active genes. Functions during the initial step of TCR in cooperation with ERCC6/CSB to recognised stalled RNA polymerase II. Location: Nucleus; Chromosome (UniProt). Locus 13q33.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Breast, Bronchus, Cerebral cortex, Cervix, Epididymis, Esophagus, Kidney, Oral mucosa.
Medium only: carcinoid, cervical cancer, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ERCC5" OR ABSTRACT:"ERCC5" OR TITLE:"ERCC excision repair 5, endonuclease" OR ABSTRACT:"ERCC excision repair 5, endonuclease" OR TITLE:"DNA excision repair protein ERCC-5" OR ABSTRACT:"DNA excision repair protein ERCC-5" OR TITLE:"ERCM2" OR ABSTRACT:"ERCM2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ERCC5, not a curated reading list.